How to Transfer an Active Study to a New IRB

How to Transfer an Active Study to a New IRB: A Step-by-Step Guide

Transferring an active clinical study from one Institutional Review Board (IRB) to another can feel daunting, but it's a common occurrence in research. Whether you're switching from a university IRB to a commercial IRB, consolidating studies under a central IRB for multi-site trials, or simply seeking better service and timelines, understanding the transfer process is essential for maintaining compliance and protecting research participants.

This comprehensive guide walks you through every step of the IRB transfer process, helping you navigate the transition smoothly while maintaining continuous ethical oversight of your research.

Common Reasons for Transferring to a New IRB

Before diving into the mechanics of transferring, it's helpful to understand why researchers and sponsors make this decision:

Improved timelines and responsiveness: Commercial IRBs often provide faster review times and more dedicated support than institutional boards
Cost considerations: Understanding IRB review fees can reveal significant savings opportunities
Single IRB mandates: NIH requirements for multi-site studies often necessitate switching to a single IRB model
Institutional changes: Researchers moving to new institutions or sponsors changing CRO partnerships
Service quality issues: Delays, communication problems, or lack of specialized expertise
Expanding study scope: Adding sites or capabilities that exceed the current IRB's capacity

Pre-Transfer Planning: Setting Yourself Up for Success

Successful IRB transfers begin with thorough preparation. Rushing the process or failing to coordinate properly can result in lapses in oversight, study delays, or regulatory complications.

Evaluate Your Current IRB Agreement

Review your existing IRB registration agreement carefully. Some IRBs require advance notice of termination (typically 30-60 days), while others may have specific procedures for active study transfers. Understanding these requirements prevents contractual issues and ensures a professional transition.

Select Your New IRB Strategically

Not all IRBs are created equal. When choosing the right IRB for your clinical trial, consider:

Relevant expertise: Does the IRB have experience with your study type (e.g., medical devices, supplements, international research)?
Review timelines: What are their average turnaround times for initial review, amendments, and continuing review?
Technology platform: Can you easily submit materials and track review status?
Responsiveness: Will you have dedicated support contacts?
Regulatory track record: Do they maintain FDA and OHRP compliance?

Communicate with Stakeholders

Inform all relevant parties of your intention to transfer:

Study sponsors and funding agencies
Principal investigators at all study sites
Regulatory affairs teams
Clinical research coordinators
Data and safety monitoring boards (if applicable)

Transparency prevents confusion and ensures everyone understands the transition timeline and their responsibilities.

The IRB Transfer Process: Step-by-Step

Step 1: Contact Your New IRB

Reach out to your prospective IRB well before you need the transfer completed. Discuss:

Your study type and population
Transfer timeline and urgency
Any upcoming deadlines (e.g., continuing review due dates)
Special requirements or concerns

Many IRBs, including Elemental IRB, assign dedicated reviewers to facilitate smooth transitions and provide personalized guidance throughout the process.

Step 2: Gather Complete Study Documentation

You'll need to provide your new IRB with comprehensive study materials. This typically includes:

Current IRB-approved protocol (latest version with all amendments)
Informed consent forms (all versions currently in use)
HIPAA authorization forms (if applicable)
Investigator brochure or product information
Recruitment materials (advertisements, scripts, etc.)
Case report forms and data collection instruments
All previous IRB approval letters and correspondence
Continuing review approval letters
Amendment history with all approved modifications
Adverse event reports submitted to the previous IRB
Current enrollment numbers and status
Consent log (dates participants were consented)

Having a complete IRB submission checklist ensures you don't miss critical documents that could delay the transfer.

Step 3: Submit Transfer Package to New IRB

Your new IRB will have a specific submission process for study transfers. Most require:

Transfer application or cover letter explaining the reason for transfer
Complete study documentation (as listed above)
Confirmation of current approval status with the previous IRB
Statement of study activities since initial approval
Current participant enrollment status

Be clear about your timeline needs and any imminent deadlines. If you have a continuing review approaching, mention this upfront so the new IRB can prioritize accordingly.

Step 4: New IRB Review Process

The new IRB will conduct a comprehensive review of your study, which may be:

Full board review: For higher-risk studies or those with complex ethical considerations
Expedited review: For minimal risk studies that qualify under federal regulations
Limited review: For studies previously approved elsewhere that meet limited review criteria

The review process typically takes 1-4 weeks, depending on the study's complexity and the type of review required. Understanding IRB approval timelines helps you plan accordingly.

The new IRB may request modifications or clarifications, particularly regarding:

Consent form language or readability
Risk/benefit descriptions
Privacy and confidentiality protections
Study procedures or safety monitoring

Step 5: Coordinate the Transition Period

Timing is critical to avoid any lapse in IRB oversight. There are two main approaches:

Option A: Overlapping Coverage (Recommended)

Maintain approval from your current IRB until you receive approval from the new IRB. This ensures continuous oversight but requires careful coordination:

Continue all reporting to current IRB until transfer is complete
Obtain approval from new IRB
Implement new IRB's approved documents (consent forms, etc.)
Formally close out with previous IRB
Begin all reporting to new IRB

Option B: Sequential Transfer

If overlapping coverage isn't feasible, you may need to pause enrollment briefly:

Stop enrolling new participants
Close out with current IRB
Obtain approval from new IRB
Resume enrollment with new IRB's approved materials

Note that continuing to collect data from already-enrolled participants typically doesn't require pausing study activities.

Step 6: Update Study Documents and Systems

Once you receive approval from your new IRB:

Replace consent forms: Begin using the new IRB-stamped consent documents for all newly enrolled participants
Update study files: Replace old IRB contact information and approval letters
Revise regulatory binders: Update essential documents at all sites
Modify ClinicalTrials.gov listing: Update the IRB of record if registered
Notify sponsors and collaborators: Provide new IRB contact information
Train study staff: Ensure all team members understand the new reporting requirements and procedures

Step 7: Close Out with Previous IRB

Provide your previous IRB with:

Formal notification of study transfer with the effective date
Final study status report including total enrollment, any unreported events, and current study phase
Copy of new IRB approval letter (if requested)
Confirmation that all outstanding requirements have been fulfilled

Maintain professional relationships—you may work with this IRB again or need to reference historical approvals.

Special Considerations for IRB Transfers

Handling Already-Enrolled Participants

Participants who provided consent under your previous IRB's approved forms generally do not need to re-consent solely because of an IRB transfer. However, re-consent may be required if:

The new IRB requires substantive changes to the consent form
Significant new information has emerged that affects the risk/benefit analysis
The consent form didn't adequately describe certain study procedures

Your new IRB will advise on whether re-consent is necessary.

Managing Continuing Review Deadlines

If your continuing review deadline is approaching:

Contact your new IRB immediately to discuss expediting the transfer
Submit continuing review to your current IRB if the transfer won't complete in time
Coordinate with both IRBs to ensure no lapse in approval

Some commercial IRBs can accommodate rush transfers to prevent study interruptions.

Multi-Site Study Transfers

For multi-site studies, the transfer process becomes more complex:

Ensure all sites are informed and agree to the transfer
Update authorization agreements between the IRB of record and relying sites
Coordinate timing so all sites transition simultaneously
Verify each site's institutional policies permit reliance on the new IRB

The NIH single IRB mandate has streamlined this process for federally-funded multi-site trials.

Addressing Pending Submissions

If you have pending submissions with your current IRB (amendments, adverse event reports, protocol deviations):

Complete review of pending items before transferring, or
Withdraw pending submissions and resubmit to the new IRB, or
Coordinate with both IRBs to transfer pending items

Discuss the best approach with both IRBs based on the urgency and nature of the pending submissions.

Common Pitfalls to Avoid

Starting Too Late

Waiting until your continuing review is overdue or your current IRB relationship is untenable makes the transfer rushed and stressful. Plan transfers well in advance—ideally 60-90 days before any critical deadlines.

Incomplete Documentation

Missing documents delay the new IRB's review. Use a comprehensive IRB submission checklist and verify you have all versions of all documents.

Poor Communication

Failing to keep all stakeholders informed creates confusion and can result in compliance issues. Maintain clear, documented communication with both IRBs, all study sites, sponsors, and regulatory authorities.

Assuming Universal Acceptance

Your new IRB may have different standards or interpretations of regulations. Be prepared to make modifications to consent forms, protocols, or procedures. Understanding common IRB rejection reasons helps you anticipate potential issues.

Neglecting Regulatory Filings

If your study involves FDA-regulated products (drugs, devices, biologics), you may need to update regulatory submissions (INDs, IDEs) to reflect the new IRB of record. Consult with your regulatory affairs team.

After the Transfer: Maintaining Compliance

Once your transfer is complete, ensure ongoing compliance with your new IRB:

Submit amendments promptly: All protocol modifications require IRB approval before implementation
Report adverse events: Follow your new IRB's specific timeline and reporting requirements
Complete continuing review: Mark your calendar for upcoming renewal deadlines
Maintain communication: Contact your IRB with questions rather than making assumptions
Archive documentation: Keep complete records of the transfer and all approvals

Is It Time to Transfer Your Study?

If you're experiencing delays, poor communication, or limited support from your current IRB, transferring to a more responsive board can accelerate your research and reduce administrative burden. The transfer process, while requiring careful planning, is straightforward when approached systematically.

Partner with Elemental IRB for Seamless Study Transfers

At Elemental IRB, we specialize in facilitating smooth transitions for active studies. Our experienced team provides:

Dedicated transfer coordinators who guide you through every step
Expedited review processes to minimize study interruptions
Transparent pricing with no hidden fees
Rapid turnaround times averaging 5-7 business days for most studies
Responsive communication with direct access to reviewers
Expertise across study types, from supplements and wellness products to medical devices and pharmaceuticals

Whether you're conducting a single-site pilot study or managing a complex multi-site clinical trial, we're committed to providing ethical oversight that supports—rather than hinders—your research goals.

Ready to transfer your study to an IRB that prioritizes your success? Contact Elemental IRB today to discuss your needs and receive a customized transfer plan. Our team is ready to help you make the transition seamlessly while maintaining the highest standards of research ethics and participant protection.